CoChat

Preclinical and clinical pharmacology of TPA023B, a GABAAreceptor α2/α3 subtype-selective partial agonist

Open access
Atack, JR, Hallett, DJ, Tye, S, Wafford, KA, Ryan, C, Sanabria-Bohórquez, SM, Eng, Wai-si, Gibson, RE, Burns, HD, Dawson, GR, Carling, RW, Street, LJ, Pike, A, De Lepeleire, I, Van Laere, K, Bormans, G, de Hoon, JN, Van Hecken, A, McKernan, RM, Murphy, MG, Hargreaves, RJ · 2011 · Journal of Psychopharmacology
Cited by 63

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

In the accompanying paper we describe how MRK-409 unexpectedly produced sedation in man at relatively low levels of GABA A receptor occupancy (∼10%). Since it was not clear whether this sedation was mediated via the α2/α3 or α1 GABA A subtype(s), we characterized the properties of TPA023B, a high-affinity imidazotriazine which, like MRK-409, has partial agonist efficacy at the α2 and α3 subtype but is an antagonist at the α1 subtype, at which MRK-409 has weak partial agonism. TPA023B gave dose- and time-dependent occupancy of rat brain GABA A receptors as measured using an in vivo [3 H]flumazenil binding assay, with 50% occupancy corresponding to a respective dose and plasma drug concentration of 0.09 mg/kg and 19 ng/mL, the latter of which was similar to that observed in mice (25 ng/mL) and comparable to values obtained in baboon and man using [11 C]flumazenil PET (10 and 5.8 ng/mL, respectively). TPA023B was anxiolytic in rodent and primate (squirrel monkey) models of anxiety (elevated plus maze, fear-potentiated startle, conditioned suppression of drinking, conditioned emotional response) yet had no significant effects in rodent or primate assays of ataxia and/or myorelaxation (rotarod, chain-pulling, lever pressing), up to doses (10 mg/kg) corresponding to occupancy of greater than 99%. In man, TPA023B was well tolerated at a dose (1.5 mg) that produced occupancy of >50%, suggesting that the sedation previously seen with MRK-409 is due to the partial agonist efficacy of that compound at the α1 subtype, and highlighting the importance of antagonist efficacy at this particular GABA A receptor population for avoiding sedation in man.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0269881109354928

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 63

Metadata

Authors
Atack, Jr., Hallett, D., Tye, S., Wafford, K., Ryan, C., Sanabria-Bohórquez, S., Eng, W.-S., Gibson, R., Burns, H., Dawson, G., Carling, R., Street, L., Pike, A., De Lepeleire, I., Van Laere, K., Bormans, G., de Hoon, J., Van Hecken, A., McKernan, R., Murphy, M., & Hargreaves, R.
Venue
Journal of Psychopharmacology
Published
2010-02-15
Volume
25
Issue
3
Pages
329-344
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2064596734
Cited by
63
References
11
FWCI
1.76
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical and clinical pharmacology of TPA023B, a GABAAreceptor α2/α3 subtype-selective partial agonist. https://app.cochat.ai/papers/10.1177/0269881109354928
The paper
Atack, Jr., Hallett, D., Tye, S., Wafford, K., Ryan, C., Sanabria-Bohórquez, S., Eng, W.-S., Gibson, R., Burns, H., Dawson, G., Carling, R., Street, L., Pike, A., De Lepeleire, I., Van Laere, K., Bormans, G., de Hoon, J., Van Hecken, A., McKernan, R., . . . Hargreaves, R. (2011). Preclinical and clinical pharmacology of TPA023B, a GABAAreceptor α2/α3 subtype-selective partial agonist. Journal of Psychopharmacology. https://doi.org/10.1177/0269881109354928

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.